Biologically Active Small Molecules

Candesartan is an inhibitor of the angiotensin II type 1 receptor (AT1) that displays antihypertensive, cardioprotective, nephroprotective, and potentially antiviral activities. In vivo, candesartan increases renal blood blow and decreases renal

An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC₅₀ values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis.

An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC₅₀ values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis.

An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC₅₀ values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis.

An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC₅₀ values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis.

An anthranilic acid derivative that activates the oxidized (heme-free) form of sGC (EC₅₀ = 0.5-10 &microM in purified bovine lung or crude human corpus cavernosum) by binding to the heme pocket and mimicking its function increases cGMP

An anthranilic acid derivative that activates the oxidized (heme-free) form of sGC (EC₅₀ = 0.5-10 &microM in purified bovine lung or crude human corpus cavernosum) by binding to the heme pocket and mimicking its function increases cGMP

An anthranilic acid derivative that activates the oxidized (heme-free) form of sGC (EC₅₀ = 0.5-10 &microM in purified bovine lung or crude human corpus cavernosum) by binding to the heme pocket and mimicking its function increases cGMP

An inhibitor of HIV-1 protease (EC50 = 2.6 nM) commonly used in vivo in combination therapy for HIV-1 infection.

An inhibitor of HIV-1 protease (EC50 = 2.6 nM) commonly used in vivo in combination therapy for HIV-1 infection.

A hybrid molecule of an H2S donor and the NSAID diclofenac that does not cause gastric damage or promote leukocyte adherence to vascular endothelium exhibits efficacy at doses of 10-50 &micromole/kg in rat.

A hybrid molecule of an H2S donor and the NSAID diclofenac that does not cause gastric damage or promote leukocyte adherence to vascular endothelium exhibits efficacy at doses of 10-50 &micromole/kg in rat.